Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 1:56:100560.
doi: 10.1016/j.ahjo.2025.100560. eCollection 2025 Aug.

Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review

Nguyen Yen Nhi Ngo  1 , Chloé Davidson Villavaso  1 , Chisom Joan Orakwue  1 , William Zachary Rowalt  1 , Madhur Roberts  1 , Keith C Ferdinand  1
Affiliations
Review

Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review

Nguyen Yen Nhi Ngo et al. Am Heart J Plus. .

Abstract

Introduction: Atherosclerosis cardiovascular disease (ASCVD), especially coronary artery disease (CAD), remains the leading cause of death worldwide, with several well-identified risk factors. This case report presents a premenopausal female with low calculated ASCVD risk, hypertension, elevated lipoprotein(a) [Lp(a)], and clinically significant CAD.

Case report: A 44-year-old premenopausal White female with controlled stage 2 hypertension, and overall low calculated 10-year ASCVD risk, was found to have severe CAD. She presented to the clinic with worsening chest discomfort during exertion and was diagnosed with a heavily calcified proximal left anterior descending artery stenosis, necessitating percutaneous coronary intervention.

Discussion: The global prevalence of elevated Lp(a) >50 mg/dL is around 1.43 billion. Elevated lipoprotein(a) is now recognized, based on the preponderance of the evidence, by several international scientific statements as an independent risk factor for ASCVD, including CAD. Nevertheless, the current 2018 American College of Cardiology (ACC) and American Heart Association (AHA) multi-society guideline on the Management of Blood Cholesterol only classifies Lp(a) as a risk enhancer. This recommendation, along with the lack of approved pharmacotherapy has contributed to limited testing in current United States clinical practice (<1 % for the general population). Furthermore, the inadequate assessment of Lp(a) may lead to an underestimation of ASCVD risk.

Conclusion: This case highlights the shortcomings of inadequate assessment of Lp(a) leading to the underestimation of cardiovascular risk. Accordingly, with multiple recent international scientific statements, clinicians should universally screen for elevated Lp(a). In the future, investigational therapies for lowering Lp(a) may be crucial for improving patient outcomes.

PubMed Disclaimer

Conflict of interest statement

Dr. Ferdinand is the steering committee chair for A Randomized Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (TQJ230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease NCT06267560 Dr. Ferdinand is an investigator for Lp(a) HORIZON is a pivotal, global multicenter, double-blind, placebo-controlled pivotal Phase 3 study conducted by Novartis NCT04023552 Chloé Davidson Villavaso is an investigator for Novartis.

Figures

Fig. 1
Fig. 1
Impact of elevated Lp(a) on cardiovascular disease risk in Women.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Koschinsky M.L., et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J. Clin. Lipidol. 2024;18(3):e308–e319. doi: 10.1016/j.jacl.2024.03.001. - DOI - PubMed
    1. Kronenberg F., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43(39):3925–3946. doi: 10.1093/eurheartj/ehac361. - DOI - PMC - PubMed
    1. Lian P., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors. Clin. Chim. Acta. 2025;565 doi: 10.1016/j.cca.2024.119982. - DOI - PubMed
    1. Martin S.S., et al. 2024 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149(8):e347–e913. doi: 10.1161/CIR.0000000000001209. - DOI - PMC - PubMed
    1. Grundy S.M., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143. doi: 10.1161/CIR.0000000000000625. - DOI - PMC - PubMed

LinkOut - more resources